Evidence map›Paper›PMID 41400781›Full record

ArticleInternational journal of hematology2026

A retrospective analysis of autologous stem cell transplantation conditioning with reduced-dose busulfan/thiotepa for patients with central nervous system lymphomas at a single institution.

Keiichiro Hattori, Naoki Kurita, Fumiaki Matsumura, Kenichi Makishima, Sakurako Suma, Yuya Sasaki, Yasuhito Suehara, Yumiko Maruyama, Tatsuhiro Sakamoto, Takayasu Kato and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Keiichiro HattoriDepartment of Hematology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Naoki KuritaDepartment of Hematology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Fumiaki MatsumuraDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Kenichi MakishimaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Sakurako SumaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Yuya SasakiDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Yasuhito SueharaDepartment of Hematology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Yumiko MaruyamaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Tatsuhiro SakamotoDepartment of Hematology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Takayasu KatoDepartment of Hematology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Hidekazu NishikiiDepartment of Hematology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Narushi SugiiDepartment of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Masahide MatsudaDepartment of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Eiichi IshikawaDepartment of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Naoshi ObaraDepartment of Hematology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Mamiko Sakata-YanagimotoDepartment of Hematology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. sakatama@md.tsukuba.ac.jp.ORCID http://orcid.org/0000-0001-7310-8045

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBusulfan (BU)- and thiotepa (TT)-containing regimens have been approved for autologous stem cell transplantation (ASCT) in central nervous system lymphoma (CNSL). However, optimal doses of these regimens remain unclear. This study retrospectively analyzed the efficacy and toxicity of the Bu2TT regimen.

methodThe study included 12 patients with CNSL who received Bu2TT (BU 3.2 mg/kg, days - 7 and - 6; TT 5 mg/kg, days - 5 and - 4) followed by ASCT at our institution after April 2020.

resultsFour patients were newly diagnosed (primary 3; secondary 1), and eight relapsed (primary 6; secondary 2). The median age was 62 years. Nine patients received high-dose MTX-based regimens as pre-transplant therapy. The other three received tirabrutinib, which was combined with localized radiotherapy (CyberKnife) in one patient. Disease status before ASCT was complete remission (CR) in 7 patients and partial remission in 5. Complications included febrile neutropenia (10/12 patients) and grade 3 anorexia (5/12 patients). Disease status after transplantation was CR in 10 patients and progressive disease in 2. OS and PFS rates at 2 years were 100% and 71%, respectively.

conclusionOur data suggest that Bu2TT had acceptable safety and efficacy. These results provide a rationale for further analyses in prospective multi-institutional trials.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBusulfanCentral Nervous System NeoplasmsHematopoietic Stem Cell TransplantationLymphomaThiotepaTransplantation ConditioningAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTransplantation, AutologousTreatment OutcomeBusulfanThiotepaAutologous stem cell transplantationBu2TTPrimary central nervous system lymphomaSecondary central nervous system lymphomaThiotepa

Identifiers

PMID41400781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.